TY - JOUR T1 - PCN259 SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY JO - Value in Health PY - 2019/05/01 AU - Hatswell AJ AU - Bullement A AU - Schlichting M AU - Bharmal M ED - DO - DOI: 10.1016/j.jval.2019.04.380 PB - Elsevier BV VL - 22 SP - S105 EP - S105 Y2 - 2025/05/28 ER -